Research ArticleOriginal Article
Open Access

The prevalence of cardiovascular disease in adults with type 2 diabetes mellitus in Saudi Arabia - CAPTURE study

Abdullah M. Alguwaihes, Amani Alhozali, Moataz M. Yahia, Tarek Abdel-Nabi, Mohamed Hassan Hatahet, Nader I. Albalkhi and Saud Al Sifri
Saudi Medical Journal January 2023, 44 (1) 57-66; DOI: https://doi.org/10.15537/smj.2023.44.1.20220402

References

  1. 1.↵
    International Diabetes Federation. IDF Diabetes Atlas. 9th edition. [Updated 2021; accessed 2022 Apr 1]. Available from: https://www.idf.org/e-library/epidemiology-research/diabetes-atlas/159-idf-diabetes-atlas-ninth-edition-2019.html
  2. 2.↵
    World Health Organization. Global report on diabetes. [Updated 2016; accessed 2022Nov 7]. Available from: https://www.who.int/publications/i/item/9789241565257
  3. 3.↵
    1. Ahmed AM,
    2. Hersi A,
    3. Mashhoud W,
    4. Arafah MR,
    5. Abreu PC,
    6. Al Rowaily MA, et al.
    Cardiovascular risk factors burden in Saudi Arabia: the Africa Middle East cardiovascular epidemiological (ACE) study. J Saudi Heart Assoc 2017; 29: 235-243.
    OpenUrl
  4. 4.↵
    1. Alzeidan R,
    2. Rabiee F,
    3. Mandil A,
    4. Hersi A,
    5. Fayed A.
    Non-communicable disease risk factors among employees and their families of a Saudi university: an epidemiological study. PLoS One 2016; 11: e0165036.
    OpenUrl
  5. 5.
    1. Memish ZA,
    2. El Bcheraoui C,
    3. Tuffaha M,
    4. Robinson M,
    5. Daoud F,
    6. Jaber S, et al.
    Obesity and associated factors--Kingdom of Saudi Arabia, 2013. Prev Chronic Dis 2014; 11: E174.
    OpenUrl
  6. 6.↵
    1. Moradi-Lakeh M,
    2. El Bcheraoui C,
    3. Tuffaha M,
    4. Daoud F,
    5. Al Saeedi M,
    6. Basulaiman M, et al.
    The health of Saudi youths: current challenges and future opportunities. BMC Fam Pract 2016; 17: 26.
    OpenUrl
  7. 7.↵
    1. Alhabib KF,
    2. Batais MA,
    3. Almigbal TH,
    4. Alshamiri MQ,
    5. Altaradi H,
    6. Rangarajan S, et al.
    Demographic, behavioral, and cardiovascular disease risk factors in the Saudi population: results from the Prospective Urban Rural Epidemiology study (PURE-Saudi). BMC Public Health 2020; 20: 1213.
    OpenUrl
  8. 8.↵
    1. Aljefree N,
    2. Ahmed F.
    Prevalence of cardiovascular disease and associated risk factors among adult population in the Gulf Region: a systematic review. Advances in Public Health 2015; 2015: 1-23.
    OpenUrl
  9. 9.↵
    General Authority for Statistics. Household sports practice survey 2021. [Updated 2021; accessed 2022 Nov 9]. Available from: https://www.stats.gov.sa/en/950-0
  10. 10.↵
    1. Roth GA,
    2. Johnson C,
    3. Abajobir A,
    4. Abd-Allah F,
    5. Abera SF,
    6. Abyu G, et al.
    Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990-2015. J Am Coll Cardiol 2017; 70: 1-25.
    OpenUrlFREE Full Text
  11. 11.↵
    World Health Organization. Noncommunicable diseases country profiles 2018. [Updated 2018; accessed 2022 Nov 7]. Available from: https://apps.who.int/iris/handle/10665/274512
  12. 12.↵
    GBD 2017 Saudi Arabia Collaborators. The burden of disease in Saudi Arabia 1990-2017: results from the Global Burden of Disease Study 2017. Lancet Planet Health 2020; 4: e195-e208.
    OpenUrlPubMed
  13. 13.↵
    American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021. Diabetes Care 2021; 44: S111-S124.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Marso SP,
    2. Bain SC,
    3. Consoli A,
    4. Eliaschewitz FG,
    5. Jódar E,
    6. Leiter LA, et al.
    Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375: 1834-1844.
    OpenUrlCrossRefPubMed
  15. 15.
    1. Marso SP,
    2. Daniels GH,
    3. Brown-Frandsen K,
    4. Kristensen P,
    5. Mann JF,
    6. Nauck MA, et al.
    Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311-322.
    OpenUrlCrossRefPubMed
  16. 16.
    1. Zinman B,
    2. Lachin JM,
    3. Inzucchi SE. Empagliflozin
    , cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2016; 374: 1094.
    OpenUrlPubMed
  17. 17.
    1. Wiviott SD,
    2. Raz I,
    3. Bonaca MP,
    4. Mosenzon O,
    5. Kato ET,
    6. Cahn A, et al.
    Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380: 347-357.
    OpenUrlCrossRefPubMed
  18. 18.
    1. Gerstein HC,
    2. Colhoun HM,
    3. Dagenais GR,
    4. Diaz R,
    5. Lakshmanan M,
    6. Pais P, et al.
    Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019; 394: 121-130.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Neal B,
    2. Perkovic V,
    3. Matthews DR.
    Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 2099.
    OpenUrlPubMed
  20. 20.↵
    1. Al-Sofiani ME,
    2. Batais MA,
    3. Aldhafiri E,
    4. Alzaid A.
    Pharmacological treatment of type 2 diabetes in Saudi Arabia: a consensus statement from the Saudi Society of Endocrinology and Metabolism (SSEM). Diabetes Metab Syndr 2021; 15: 891-899.
    OpenUrl
  21. 21.↵
    1. Mosenzon O,
    2. Alguwaihes A,
    3. Leon JLA,
    4. Bayram F,
    5. Darmon P,
    6. Davis TME, et al.
    CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries. Cardiovasc Diabetol 2021; 20: 154.
    OpenUrl
  22. 22.↵
    World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013; 310: 2191-2194.
    OpenUrlCrossRefPubMedWeb of Science
  23. 23.↵
    1. Berger ML,
    2. Sox H,
    3. Willke RJ,
    4. Brixner DL,
    5. Eichler HG,
    6. Goettsch W, et al.
    Good practices for real-world data studies of treatment or comparative effectiveness: recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making. Pharmacoepidemiol Drug Saf 2017; 26: 1033-1039.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Sarwar N,
    2. Gao P,
    3. Seshasai SR,
    4. Gobin R,
    5. Kaptoge S,
    6. Di Angelantonio E, et al.
    Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375: 2215-2222.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    1. Matsushita K,
    2. van der Velde M,
    3. Astor BC,
    4. Woodward M,
    5. Levey AS,
    6. de Jong PE, et al.
    Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375: 2073-2081.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.
    1. Khan SS,
    2. Ning H,
    3. Wilkins JT,
    4. Allen N,
    5. Carnethon M,
    6. Berry JD, et al.
    Association of body mass index with lifetime risk of cardiovascular disease and compression of morbidity. JAMA Cardiol 2018; 3: 280-287.
    OpenUrl
  27. 27.↵
    1. Kondo T,
    2. Nakano Y,
    3. Adachi S,
    4. Murohara T.
    Effects of tobacco smoking on cardiovascular disease. Circ J 2019; 83: 1980-1985.
    OpenUrl
  28. 28.↵
    1. Al-Nozha MM,
    2. Arafah MR,
    3. Al-Mazrou YY,
    4. Al-Maatouq MA,
    5. Khan NB,
    6. Khalil MZ, et al.
    Coronary artery disease in Saudi Arabia. Saudi Med J 2004; 25: 1165-1171.
    OpenUrlPubMed
  29. 29.↵
    1. Senitan M,
    2. Alhaiti AH,
    3. Gillespie J,
    4. Alotaibi BF,
    5. Lenon GB.
    The referral system between primary and secondary health care in Saudi Arabia for patients with type 2 diabetes: a systematic review. J Diabetes Res 2017; 2017: 4183604.
    OpenUrl
  30. 30.↵
    1. Al-Saleem SA,
    2. Al-Shahrani A,
    3. Al-Khaldi YM.
    Hypertension care in Aseer region, Saudi Arabia: barriers and solutions. Saudi J Kidney Dis Transpl 2014; 25: 1328-1333.
    OpenUrl
  31. 31.↵
    1. Au Yeung SL,
    2. Luo S,
    3. Schooling CM.
    The impact of glycated hemoglobin (HbA1c) on cardiovascular disease risk: a Mendelian randomization study using UK Biobank. Diabetes Care 2018; 41: 1991-1997.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Aljehani MM,
    2. Mohamed AM,
    3. Ali AH,
    4. Alhaeti HR,
    5. Alribh FM,
    6. Alharbi FA, et al.
    Prevalence of diabetic complications in relation to risk factors among patients with type 2 diabetes at university hospital in Riyadh, Saudi Arabia. EC Endocrinology and Metabolic Research 2020; 5: 1-8.
    OpenUrl
  33. 33.↵
    1. Alaboud AF,
    2. Tourkmani AM,
    3. Alharbi TJ,
    4. Alobikan AH,
    5. Abdelhay O,
    6. Al Batal SM, et al.
    Microvascular and macrovascular complications of type 2 diabetic mellitus in Central, Kingdom of Saudi Arabia. Saudi Med J 2016; 37: 1408-1411.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords